Compugen Stock Price

0.10 (1.18%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Compugen Ltd CGEN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.10 1.18% 8.60 18:00:06
Open Price Low Price High Price Close Price Prev Close
8.50 8.295 8.69 8.60 8.50
Bid Price Ask Price Spread News
8.23 8.67 0.44 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
7,842 875,490 $ 8.56 $ 7,491,907 1,375,352 7.10 - 19.90
Last Trade Time Type Quantity Stock Price Currency
16:00:40 formt 1,349 $ 8.60 USD

Compugen Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 711.17M 82.69M 57.28M $ - $ - -0.43 -35.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Compugen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CGEN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week8.778.967.968.52689,231-0.17-1.94%
1 Month8.149.307.49018.481,190,0650.465.65%
3 Months11.6814.177.109.661,447,615-3.08-26.37%
6 Months14.0715.167.1011.261,284,191-5.47-38.88%
1 Year14.9519.907.1013.681,386,906-6.35-42.47%
3 Years4.0519.902.0011.46664,4864.55112.35%
5 Years7.0419.902.0010.55460,6381.5622.16%

Compugen Description

Compugen Ltd is a therapeutic discovery company. It is involved in the business of using its predictive discovery infrastructure to identify novel drug targets and develop biologics. The firm's therapeutic pipeline mainly consists of early-stage immuno-oncology programs aimed at harnessing the immune system to fight cancer. It focuses on immune checkpoint target candidates which are predicted to serve drug targets for cancer immunotherapies addressing various cancer types and also autoimmune diseases.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.